Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T-19
- Development stage
- Phase 1
- Lead developer
- Beijing Yongtai Ruike Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR-T-19 is a cell therapy utilizing T cells that have been genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 protein. This investigational biological treatment is being developed for various CD19-positive hematological malignancies, including relapsed/refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The therapy aims to harness the patient's own immune system to recognize and eliminate cancer cells expressing CD19.
- Other names
- RC19D2RC-19D2RC 19D2dinorencel
02
Targets
Beyond the preview
Go deeper on CAR-T-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T-19.